Conferences: ACNP

ACNP

ACNP 2023

KarXT (Xanomeline–Trospium) for the Treatment of Agitation in Schizophrenia: PANSS–EC Results from Three Randomized, Double-Blind, Placebo-Controlled Trials

ACNP 2023

KarXT (Xanomeline–Trospium) Demonstrates Broad Efficacy in People With Schizophrenia Across a Wide Range of Demographic Subgroups: Pooled Results From the 3 Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials

ACNP 2023

The Muscarinic Agonist Xanomeline Demonstrates Antipsychotic Activity and Augments Clinical Antipsychotics in Rodent Behavioral Models of Psychosis

ACNP 2022

Safety and Efficacy of KarXT (Xanomeline–Trospium) in Patients With Schizophrenia: Results From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (EMERGENT-2)

ACNP 2021

Xanomeline’s Activity in Rodent Models of Psychosis: Role of Central Muscarinic Receptors and Augmentation by Risperidone and Aripiprazole

ACNP 2020

Molecular Mechanism of Antipsychotic Xanomeline’s Selectivity at Muscarinic Receptors

ACNP 2020

The M1/M4 Agonist Xanomeline, in Combination With the Peripheral Anticholinergic Trospium, Is Effective for Acute Treatment of Schizophrenia: Results of a Phase 2 RCT Comparing KarXT vs Placebo